RFP
PLX icon

Root Financial Partners’s Protalix BioTherapeutics PLX Stock Holding History

Root Financial Partners’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-128
Closed -$278 – 2430
2026
Q1 		$278 Buy
+128
New +$318 ﹤0.01% 3068

Other funds holding PLX

New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HIM
Harbour Investment Management Edmonds, Washington $194M AUM 15.93% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
IRAG
Investment Research & Advisory Group Atlanta, Georgia $324M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Root Financial Partners's PLX Position: Q2 2026 in Review

Root Financial Partners sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 128 shares — an estimated $278 sold.

Root Financial Partners first reported a position in PLX in Q1 2026 and held it in 1 quarter. The position peaked at $278 in Q1 2026. 18 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Root Financial Partners reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 128 Protalix BioTherapeutics shares in Q2 2026, an estimated $278.
  • Root Financial Partners first reported a position in Protalix BioTherapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Protalix BioTherapeutics position peaked at $278 in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.